Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 11:01 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Stock Picks » Strong Buy: TNXP (MC $32M) (Cash $34M) O/S 7.5 M / Phase 3 Data in 1H 2018 =More than just cheap



Reply
 
Thread Tools Search this Thread
Old 09-22-2017, 10:18 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 105
Reputation: 36
Biohero is on a distinguished road
Default TNXP (MC $32M) (Cash $34M) O/S 7.5 M / Phase 3 Data in 1H 2018 =More than just cheap

Found another terrible undervalued which trading below Cash and which is close to phase 3 readout if successfull the drug will have around $600+ M Market Potential . The Company has only 7.5 Million Shares outstanding and Baker bros who are really one of the most successful investors in the Biotech Sector is second largest staekholder . TNXP should be valued right now around $15 per share for their Phase 3 program and huge cash balance and if phase 3 outcome is positive then sky is the limit .GL


Tonix Pharma (TNXP)

Market Cap: $32 Million
Cash: $34.5 Million
Kurs: $4.25

Shares Out: 7.5 Million


New Presentation
http://content.equisolve.net/tonixph...179cb3f7c8.pdf


Phase 3 HONOR study of Tonmya in military-related PTSD enrolling
•Encouraging evidence of safety and efficacy was demonstrated in Phase 2

Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA)
•Expedited development and accelerated review are expected
•Potential to file NDA based on one Phase 3 study if data are statistically persuasive

Proposed registration plan agreed by the FDA
•Additional nonclinical safety and clinical abuse potential studies are not required

Patent protection through 2034 in U.S.
•Composition of matter patent for eutectic, required for transmucosal delivery of cyclobenzaprine



TNXP: Patient Enrollment Continues for Phase 3 Study of Tonmya® in PTSD; Interim Analysis Expected in 1H18
https://finance.yahoo.com/news/tnxp-...161500725.html

Conclusion and Valuation

The U.S. military’s intense interest in identifying safe and effective PTSD treatments is important for Tonix, as the AtEase study is the only controlled clinical trial to show a benefit in treating military related PTSD. If those results can be duplicated in the HONOR study (and Tonmya® gets approved), the Department of Defense and the VA would likely be very interested in getting the treatment to military personnel and veterans who suffer from PTSD.

Our valuation for Tonix is derived from a probability adjusted discounted cash flow model that takes into account potential future revenues from the sale of TNX-102 SL in PTSD. Of the approximately 8.6 million individuals in the U.S. who suffer from PTSD, it’s estimated that approximately 20% seek treatment. With a peak market share of only 6%, we currently estimate that peak sales of $650 million are possible. Using a discount rate of 18% and a 50% probability of approval leads to a net present value for the PTSD program of $67 million. Combined with the company’s current cash position and dividing by a reasonable fully diluted share count of 8.1 million shares leads to a valuation of approximately $13 per share.



Insider & Institutional Ownership :

Rosalind Advisors, Inc. 553 908
Baker Bros. Advisors LP 510 922
B. Riley Capital Management LLC 378 138
Opaleye Management, Inc. 370 000
Empery Asset Management LP 315 000
The Vanguard Group, Inc. 184 377
Heights Capital Management, Inc. 89 713
Seth Lederman, MD 83 400
Ernest Mario, PhD 69 718
Kingdon Capital Management LLC 64 549






Biohero is offline   Rate this post Yes | No Reply With Quote
Old 09-27-2017, 11:13 AM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 105
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

trading below cash of $34 million + only 7.5 million shares outstanding + attractive product in phase 3 with results expected in 1H 2018 = The definition of a dirt cheap stock .GL

Biohero is offline   Rate this post Yes | No Reply With Quote
Old 09-28-2017, 09:26 AM   Nav to Top  #3
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 105
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

IF P3 is successful then this stock could hit $80-100 per share (= Mcap $600-750M) thats not much for a Drug with $650 million potential.GL

Tonix's Tonmya Treats PTSD By Helping Sufferers Sleep Better ..Sep.27.17
https://seekingalpha.com/article/410...s-sleep-better

Summary

PTSD is a serious illness that has devastating symptoms. It affects 3.5% of American adults, or 8.6m individuals each year. The prevalence of PTSD is even higher among veterans.

The only FDA approved PTSD drug treatment, the SSRIs (selective serotonin reuptake inhibitors), failed to show efficacy in military-related PTSD and have serious side effects.

Tonix's Tonmya is being studied in HONOR, a phase 3 trial for treating military-related PTSD. Tonmya works by improving sleep quality and allowing the mind to heal itself.

This article focuses on PTSD and discusses how Tonmya can meet a very important unmet medical need.
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 09-29-2017, 10:18 AM   Nav to Top  #4
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 105
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Another green day maybe it will hit $5 today

trading below cash , very low market cap of only $33 million , only 7.5 million shares outstanding , Baker bros one of the most successful investors in sector ups their stake , attractive product in advanced phase 3 trial with results in 1H 2018 , $650 million sales potential = A MEGA OPPORTUNITY HERE it will move up faster the closer we get to the phase3 results .
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 10-04-2017, 10:46 AM   Nav to Top  #5
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 251
Favorites: Aapl celg onxx
Rep Power: 105
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Another good day but real jump will start once we hit the $5 mark because many Institutions who are not allowed to buy stock under $5 will start jump in . Stock is still a gift here trading at Cash and with a advanced Phase 3 program close to readout .GL
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 10-06-2017, 03:00 PM   Nav to Top  #6
Thusney
Junior Trader
 
Thusney's Avatar
 
Join Date: Sep 2017
Location: TORONTO
Posts: 5
Favorites: BABA
Rep Power: 26
Reputation: 10
Thusney is on a distinguished road
Default

By using BI Analyzing System, the result of this stock as shown in the below:


The last arrow is on 2017/Aug/24, and that is an UP arrow, which means it is THE GOOD TIME TO BUY this stock.



***“BI Analyzing System” can download from Apple Store / Google Play for free to use.***
Attached Images
File Type: jpeg tnxp.jpeg (27.3 KB, 2 views)
Thusney is offline   Rate this post Yes | No Reply With Quote
Old 01-23-2018, 04:48 AM   Nav to Top  #7
antsrants
Senior Trader
 
antsrants's Avatar
 
Join Date: Aug 2017
Location: Frankfurt
Posts: 104
Favorites: YTEN, USAS, RQB, USAU
Rep Power: 30
Reputation: 17
antsrants is on a distinguished road
Default

This stock I like. Good upside potential imo.
antsrants is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: AXSM (MC $83 M)(Cash $50 M) 4x BIG Phase 3 Ongoing =TOP PICK Biohero US Stock Picks 25 01-18-2018 09:22 AM
Strong Buy: Cipher Pharma - PartnerDeal & Phase 3 data this Q (Mcap 31M) biotechmaster Canadian Stock Picks 1 05-27-2011 08:12 AM
Strong Buy: CLSN// Phase 3 interim data this Q = Multibagger Potential biotechmaster US Stock Picks 1 05-04-2011 09:52 AM
Buy: USDA approval + Phase 3 data in 3Q 2010 =Excellent Opportunity !!! biotechmaster Canadian Stock Picks 15 10-18-2010 06:47 AM
Any data out there on what percentage of drugs past phase III get FDA approval? Billy Traders Lounge 1 05-30-2009 07:40 PM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On